Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype

Journal of Cellular Physiology

Volumn 228, Issue 3, 2013, Pages 556-562

  Wang, Zhiwei ^a,b   Ali, Shadan ^a   Banerjee, Sanjeev ^a   Bao, Bin ^a   Li, Yiwei ^a   Azmi, Asfar S ^a   Korc, Murray ^c   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BENGBU MEDICAL COLLEGE   (China)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; K RAS PROTEIN; PLATELET DERIVED GROWTH FACTOR D; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE DELETION; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PANCREAS; PANCREAS ADENOCARCINOMA; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; WESTERN BLOTTING;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; GENES, RAS; HUMANS; LYMPHOKINES; MICE; MICE, TRANSGENIC; MUTATION; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PHENOTYPE; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION;

MUS; MUS MUSCULUS;

EID: 84870442715     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24162     Document Type: Article

References (37)

1. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. 2003. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17: 3112- 3126.
2. Ahmad A, Wang Z, Kong D, Ali R, Ali S, Banerjee S, Sarkar FH. 2011. Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways. Breast Cancer Res Treat 126: 15- 25.
3. Ali S, Banerjee S, Logna F, Bao B, Philip PA, Korc M, Sarkar FH. 2011. Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J Cell Physiol 227: 3373- 3380.
4. Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Banerjee S, Aboukameel A, Padhye S, Philip PA, Sarkar FH. 2011a. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 6: e17850.
5. Bao B, Wang Z, Ali S, Kong D, Banerjee S, Ahmad A, Li Y, Azmi AS, Miele L, Sarkar FH. 2011b. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem 112: 2296- 2306.
6. Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, Banerjee S, Azmi AS, Miele L, Sarkar FH. 2011c. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 63: 26- 36.
7. Brembeck FH, Schreiber FS, Deramaudt TB, Craig L, Rhoades B, Swain G, Grippo P, Stoffers DA, Silberg DG, Rustgi AK. 2003. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer Res 63: 2005- 2009.
8. Cano CE, Motoo Y, Iovanna JL. 2010. Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. Scientific World J 10: 1947- 1957.
9. Deramaudt T, Rustgi AK. 2005. Mutant KRAS in the initiation of pancreatic cancer. Biochim Biophys Acta 1756: 97- 101.
10. Devarajan E, Song YH, Krishnappa S, Alt E. 2011. Epithelial-mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells. Int J Cancer 131: 1023- 1031.
11. Gidekel Friedlander SY, Chu GC, Snyder EL, Girnius N, Dibelius G, Crowley D, Vasile E, DePinho RA, Jacks T. 2009. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 16: 379- 389.
12. Grippo PJ, Tuveson DA. 2010. Deploying mouse models of pancreatic cancer for chemoprevention studies. Cancer Prev Res (Phila) 3: 1382- 1387.
13. Hanlon L, Avila JL, Demarest RM, Troutman S, Allen M, Ratti F, Rustgi AK, Stanger BZ, Radtke F, Adsay V, Long F, Capobianco AJ, Kissil JL. 2010. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res 70: 4280- 4286.
14. Hotz B, Arndt M, Dullat S, Bhargava S, Buhr HJ, Hotz HG. 2007. Epithelial to mesenchymal transition: Expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res 13: 4769- 4776.
15. Iyer RV, Gibbs J, Kuvshinoff B, Fakih M, Kepner J, Soehnlein N, Lawrence D, Javle MM. 2007. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: A single-institution prospective study. Ann Surg Oncol 14: 3202- 3209.
16. Ji B, Tsou L, Wang H, Gaiser S, Chang DZ, Daniluk J, Bi Y, Grote T, Longnecker DS, Logsdon CD. 2009. Ras activity levels control the development of pancreatic diseases. Gastroenterology 137: 1072- 1082.
17. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. 2001. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410: 1111- 1116.
18. Kong D, Banerjee S, Huang W, Li Y, Wang Z, Kim HR, Sarkar FH. 2008a. Mammalian target of rapamycin repression by 3, 3′-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res 68: 1927- 1934.
19. Kong D, Wang Z, Sarkar SH, Li Y, Banerjee S, Saliganan A, Kim HR, Cher ML, Sarkar FH. 2008b. Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 26: 1425- 1435.
20. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR, Sarkar FH. 2009. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 27: 1712- 1721.
21. Kong D, Li Y, Wang Z, Sarkar FH. 2011. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: Are they cousins or twins? Cancers (Basel) 3: 716- 729.
22. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704- 715.
23. Polyak K, Weinberg RA. 2009. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265- 273.
24. Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X, Goggins M, Iacobuzio-Donahue C, Berman DM, Laheru D, Jimeno A, Hidalgo M, Maitra A, Matsui W. 2010. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 102: 340- 351.
25. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL, Weinberg RA. 2011. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145: 926- 940.
26. Seeley ES, Carriere C, Goetze T, Longnecker DS, Korc M. 2009. Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. Cancer Res 69: 422- 430.
27. Sethi S, Sarkar FH, Ahmed Q, Bandyopadhyay S, Nahleh ZA, Semaan A, Sakr W, Munkarah A, Ali-Fehmi R. 2011. Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl Oncol 4: 222- 226.
28. Siegel R, Naishadham D, Jemal A. 2012. Cancer statistics, 2012. CA Cancer J Clin 62: 10- 29.
29. Thiery JP, Acloque H, Huang RY, Nieto MA. 2009. Epithelial-mesenchymal transitions in development and disease. Cell 139: 871- 890.
30. Ustach CV, Kim HR. 2005. Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol 25: 6279- 6288.
31. Ustach CV, Huang W, Conley-LaComb MK, Lin CY, Che M, Abrams J, Kim HR. 2010. A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate cancer. Cancer Res 70: 9631- 9640.
32. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. 2006. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 66: 2778- 2784.
33. Wang Z, Kong D, Banerjee S, Li Y, Adsay NV, Abbruzzese J, Sarkar FH. 2007. Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res 67: 11377- 11385.
34. Wang Z, Kong D, Li Y, Sarkar FH. 2009. PDGF-D signaling: A novel target in cancer therapy. Curr Drug Targets 10: 38- 41.
35. Wang Z, Ahmad A, Li Y, Kong D, Azmi AS, Banerjee S, Sarkar FH. 2010. Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta 1806: 122- 130.
36. Wang Z, Banerjee S, Ahmad A, Li Y, Azmi AS, Gunn JR, Kong D, Bao B, Ali S, Gao J, Mohammad RM, Miele L, Korc M, Sarkar FH. 2011a. Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-kappaB signaling pathways. PLoS ONE 6: e20537.
37. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D, Sarkar FH. 2011b. Pancreatic cancer: Understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8: 27- 33.